
TechTalk: Smarter LC investments that improve efficiency in biopharma labs
Friday, May 29 at 15:30 BST | 16:30 CEST | 10:30 EDT | 07:30 PDT
Advancing biopharma pipelines requires analytical workflows that can keep pace with growing molecular complexity while still meeting strict validation expectations. For many teams, this means finding ways to innovate without disrupting proven LC methods or compromising data integrity.
Yet balancing these pressures can be difficult. As assays become more demanding, traditional approaches often lead to bottlenecks, increased manual effort, or systems pushed beyond their intended limits, all while regulated environments leave little room for trial and error.
In this SelectScience® TechTalk, Dr. Andreas Mielcarek, Global Product Manager, Agilent Technologies will share how the latest innovations in the Agilent Infinity III LC Series help biopharma laboratories enhance efficiency and confidence in results. In 20 minutes, you will learn how to combine the robustness of Agilent HPLC and UHPLC systems with new capabilities that streamline workflows and reduce operational burden.
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers

Who should attend?
- Professionals in biopharmaceuticals
- Lab managers
- Analytical chemists
- Professionals working with UHPLC/HPLC
What will this webinar cover?
- How biopharma labs can balance validation constraints with escalating pipeline complexity to protect existing Infinity II systems while selectively adopting new capabilities where they deliver the most impact.
- How pressure limits, surface chemistry, and smart automation can be tailored to different biopharma assays to improve robustness, recovery, and throughput without over engineering or overspending.
- How a unified Infinity II and Infinity III ecosystem, enhanced with smart sensing and flexible sampling, can reduce failures, expand assay coverage per system, and extend the lifetime value of every LC investment.
